Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Complement C5a receptor antagonist

Tavneos (avacopan)

An approved treatment for Granulomatosis with Polyangiitis.

FDA Approved (2021)by ChemoCentryx, a wholly owned subsidiary of Amgen
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2021

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Avacopan wherever you encounter it, plus the key facts at a glance.

Generic name
Avacopan
Brand name
Tavneos
Development code
CCX168
Drug class
Complement C5a receptor antagonist
Manufacturer
ChemoCentryx, a wholly owned subsidiary of Amgen
How it's taken
Oral capsules, twice a day with food

A capsule taken twice a day with food, added to standard treatment that includes steroids (glucocorticoids), for adults with severe active ANCA-associated vasculitis, which covers granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)[1].

  • The FDA approved it on October 7, 2021[2].
  • On April 27, 2026, the FDA's drug center (CDER) proposed withdrawing that approval, saying unblinded study staff manipulated the results of the main study and citing serious liver injury cases with fatal outcomes[3].
  • Amgen, which owns the application holder ChemoCentryx, disagrees and has asked for a hearing.
  • Tavneos stays on the US market until the FDA Commissioner decides or the company removes it, and no final decision had been published as of November 14, 2026[3][8].
Follow Tavneos by email

We'll email you when Tavneos's FDA label changes, when the FDA acts on it, and when new trials for Granulomatosis with Polyangiitis open. Unsubscribe anytime.

You'll get, for Granulomatosis with Polyangiitis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Avacopan fits

Tavneos (avacopan) is a twice-daily pill approved as an add-on to standard treatment, including steroids, for adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), and the FDA's drug center proposed withdrawing that approval on April 27, 2026.

  • In the Tavneos main trial, every person with GPA or MPA also got rituximab or cyclophosphamide followed by azathioprine, alongside either Tavneos or a prednisone taper[13].
  • Rituximab (Rituxan) is FDA approved with glucocorticoids for GPA and MPA in adults and children 2 and older[16].
  • The Tavneos trial compared Tavneos with a prednisone taper, and the FDA says its week-52 result cannot be relied on, while a Duke re-review commissioned by Amgen found remission at week 26 similar in both groups.
  • Anyone taking or considering Tavneos for GPA or MPA can ask their doctor what the FDA's proposal means for them and how often their liver tests should be checked.

How Avacopan works

Granulomatosis with polyangiitis (GPA) inflames small and medium blood vessels, mostly in the nose, sinuses, lungs, airways and kidneys, and about 90% of people with GPA carry an abnormal immune protein called ANCA (anti-neutrophil cytoplasmic antibody), which triggers inflammation when it attaches to its target[15]. Microscopic polyangiitis (MPA) is a related ANCA-associated vasculitis, and the Tavneos label covers both[1].

Complement is a set of immune proteins in the blood. When it is switched on, it releases a small fragment called C5a, which acts as a signal that activates neutrophils, a type of white blood cell, and draws them toward tissue. Avacopan blocks the receptor that C5a binds to (C5aR), so C5a cannot activate and recruit neutrophils that way. The label says the exact way this produces a benefit in ANCA-associated vasculitis has not been definitively established[1].

Tavneos is an add-on. The label says it is used together with standard treatment, including glucocorticoids, and that it does not remove the need for glucocorticoids[1].

Side effects and safety

What patients report
Label warnings
  • Liver injury. Serious liver injury, including vanishing bile duct syndrome with fatal cases, has been reported. Liver tests (ALT, AST, alkaline phosphatase and total bilirubin) are checked before starting, every 4 weeks for the first 6 months, then as needed; the label suggests checks every 2 weeks for the first 3 months for people of Japanese descent. Tavneos is stopped for set liver test levels or for jaundice or itching, and stopped for good if vanishing bile duct syndrome is suspected.
  • Chronic liver disease. Not recommended for people with active, untreated or uncontrolled chronic liver disease, such as chronic active hepatitis B, untreated hepatitis C or uncontrolled autoimmune hepatitis, or with cirrhosis.
  • Angioedema. Swelling under the skin occurred in 2 people in the trials, 1 of them hospitalized. Tavneos is stopped right away and not restarted unless another cause is found.
  • Hepatitis B reactivation. Everyone is tested for hepatitis B before starting. People with current or past infection are watched during treatment and for 6 months after.
  • Serious infections. Serious infections, some fatal, have occurred, most often pneumonia and urinary tract infections. The label says to avoid Tavneos during an active serious infection.
Most common in trials
Nausea (23.5% on Tavneos against 20.7% on a prednisone taper)Headache (20.5% against 14.0%)High blood pressure (18.1% against 17.7%)Diarrhea (15.1% against 14.6%)Vomiting (15.1% against 12.8%)Rash (11.4% against 7.9%)Fatigue (10.2% against 9.1%)
What gets monitored
  • Liver tests before starting, every 4 weeks for the first 6 months, then as needed
  • For people of Japanese descent, liver tests every 2 weeks for the first 3 months, then every 4 weeks for the next 3 months
  • Hepatitis B blood tests (HBsAg and anti-HBc) before starting
  • Watch for signs of infection, jaundice, dark urine, itching or swelling of the face, lips or throat
Report a suspected reaction to Amgen at 1-800-772-6436 or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

Tavneos has no boxed warning[1]. Its label, revised in May 2026, warns first about liver damage: serious liver injury has occurred, people on Tavneos had more liver enzyme rises and liver and bile events than people on a prednisone taper in the main trial, and vanishing bile duct syndrome (a condition in which the small bile ducts in the liver are gradually destroyed) has been reported after approval, including fatal cases, mostly in Japan in people 65 and older[1].

In a March 31, 2026 safety communication, the FDA said its review of reports through October 9, 2024 found 76 cases of drug-induced liver injury with reasonable evidence of a link to avacopan, 8 of them fatal, and 7 biopsy-confirmed cases of vanishing bile duct syndrome, 3 of them fatal[5]. Amgen reports that its Japanese partner Kissei found 20 fatal serious liver injury cases among more than 8,500 patients in Japan, a count Amgen says includes cases where a link to Tavneos could not be determined[6].

The label also warns about angioedema (swelling under the skin, seen in 2 people in the trials, 1 of them hospitalized), hepatitis B coming back in people who have had it, and serious infections, including fatal ones, most often pneumonia and urinary tract infections[1].

In the main trial, side effects seen in at least 5% of people and more often than on the prednisone taper included nausea (23.5% against 20.7%), headache (20.5% against 14.0%), high blood pressure (18.1% against 17.7%), diarrhea (15.1% against 14.6%), vomiting (15.1% against 12.8%), rash (11.4% against 7.9%), fatigue (10.2% against 9.1%), upper belly pain (6.6% against 6.1%), dizziness (6.6% against 6.1%), a rise in blood creatinine (6.0% against 4.9%) and tingling or numbness (5.4% against 4.3%)[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Avacopan

The dose is 30mg, taken as three 10mg capsules, twice a day with food. Capsules are swallowed whole and not crushed, chewed or opened. A missed dose is skipped and the next dose taken at the usual time, without doubling up[1]. Tavneos is taken together with standard treatment that includes glucocorticoids[1]. Avacopan is broken down by the liver enzyme CYP3A4, so the label lowers the dose to 30mg once a day alongside strong CYP3A4 blockers such as itraconazole and says to avoid medicines that speed that enzyme up, such as rifampin.

Avacopan itself slows CYP3A4, so the label limits simvastatin to 10mg a day (20mg for people who already tolerated 80mg a day for at least a year) and says doses of other CYP3A4-processed medicines may need lowering[1]. The label gives no dose change for mild or moderate liver impairment (Child-Pugh A or B), has no data in severe impairment (Child-Pugh C) and does not recommend Tavneos with cirrhosis[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Tavneos

With private insurance, the drugmaker's copay card can lower what you pay for Tavneos. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Granulomatosis with Polyangiitis was open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Tavneos (Avacopan)
Some details not published
  • Copay help

    TAVNEOS Copay Program: eligible commercially insured patients may pay as little as $0 for a month's supply. Eligibility criteria and program maximums apply; the page does not list the maximum. Not open to patients whose prescriptions are reimbursed under any federal, state or government-funded healthcare program, or to cash patients. Full terms at tavneos.com/copay.

    For: private insurance · source
  • Free medicine program

    People without insurance or who cannot afford Tavneos may be eligible to receive it through Amgen's nonprofit patient assistance program, after an application and eligibility screening. The page does not give income limits.

    For: no insurance, underinsured · source
  • Insurance and case manager help

    TAVNEOS Connect services are for adults whose diagnosis matches the FDA-approved use. Call 1-833-TAVNEOS (1-833-828-6367), Monday to Friday, 8 AM to 8 PM ET. Amgen says time to fill is 7 days or less for most patients.

    The official page does not say who qualifies. Ask the program. · source

Good to know: Terms read on tavneos.com/support/paying-for-tavneos on November 14, 2026. The copay maximum and the free-drug income limits are not published on that page; tavneos.com/copay was not read. The FDA's drug center proposed withdrawing Tavneos on April 27, 2026; Amgen says it remains available in the US while the hearing request is pending. Questions about the proposal go to Amgen Medical Information at 1-800-772-6436 (Monday to Friday, 8 AM to 8 PM ET), per amgen.com/tavneos-update.

Checked on the drugmaker's official pages on November 14, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Granulomatosis with Polyangiitis

  • From a charity · HealthWell Foundation
    ANCA-Associated Vasculitis and Granulomatosis with Polyangiitis fund
    Open

    Pays for: Copays, premiums or other treatment costs.

Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Granulomatosis with Polyangiitis →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Access and eligibility

Manufacturer
ChemoCentryx, a wholly owned subsidiary of Amgen
Eligibility requirement

Adults with severe active ANCA-associated vasculitis, meaning granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), as an add-on to standard treatment that includes glucocorticoids. Safety and effectiveness in children have not been established. Not recommended with active, untreated or uncontrolled chronic liver disease or cirrhosis, and not used in anyone with a serious allergy to avacopan or its ingredients.

Source: TAVNEOS Connect (Amgen)

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Clinical trial results

The main trial (NCT02994927, called ADVOCATE) randomly assigned 330 people aged 13 to 88 (average age 60.9) with ANCA-associated vasculitis to Tavneos 30mg twice a day for 52 weeks or to a prednisone taper over 20 weeks, each with a dummy version of the other, on top of rituximab or cyclophosphamide followed by azathioprine[1][13]. ClinicalTrials.gov lists 331 people enrolled; the label analyzes 330[13][1].

The label reports remission at week 26 in 72.3% on Tavneos and 70.1% on prednisone (a difference of 3.4%, 95% confidence interval -6.0% to 12.8%), and sustained remission at week 52 in 65.7% against 54.9%, a difference of 12.5% (p=0.013)[1].

The FDA's April 2026 notice says those week-52 numbers are not reliable. According to the Federal Register notice, the first analysis after the trial was unblinded on November 5, 2019 did not show a statistically significant week-52 result (p=0.1025); unblinded study personnel then picked 9 patients, 6 on avacopan and 3 on prednisone, for re-review, 5 people on avacopan were reclassified as being in sustained remission, and the database was locked again on November 20, 2019, giving the p=0.0132 result that was submitted.

The FDA says the first analysis and the re-reviews were not disclosed to it[4]. The New England Journal of Medicine retracted the 2021 ADVOCATE paper on June 29, 2026[9]. Amgen says a 2026 re-review of the trial by the Duke Clinical Research Institute found remission at week 26 in 68.1% against 67.1%, still showing Tavneos was not worse, and sustained remission at week 52 in 61.4% against 52.4%, a difference of 9.8% whose 95% confidence interval runs from -0.3 to 19.9, so the week-52 advantage was not shown on that re-review[7].

Amgen lists an ongoing Phase 3 open-label study of Tavneos with rituximab or cyclophosphamide in children 6 to under 18 with ANCA-associated vasculitis (NCT06321601), which ClinicalTrials.gov lists as active but no longer recruiting[8][14].

Development history

ChemoCentryx developed avacopan under the code CCX168[13]. The FDA approved Tavneos on October 7, 2021 as a new molecular entity with orphan status[2]. ChemoCentryx is now a wholly owned subsidiary of Amgen[3]. On March 31, 2026, the FDA issued a drug safety communication on serious liver injury[5].

On April 27, 2026, CDER proposed withdrawing approval and offered the company a hearing, on 2 grounds: a lack of substantial evidence that Tavneos works, and untrue statements of material fact in the application; the notice was published in the Federal Register on April 30, 2026, under docket FDA-2026-N-1321[3][4]. The label updated in May 2026 reports the stronger liver warning and monitoring schedule, which Amgen says took effect May 29, 2026[1][7].

Amgen requested a hearing by the June 1, 2026 deadline and sent the FDA data and analyses on July 23, 2026[6][8]. Outside the US, the European Commission revoked the EU marketing authorization on August 4, 2026, after the EMA's committee recommended it on June 26, 2026[10][11]. The UK regulator, the MHRA, stopped new patients from starting the drug (sold there as Avacopan Vifor) from September 1, 2026, and plans to revoke the UK license on March 1, 2027[12].

In its November 3, 2026 quarterly results, Amgen said it continues to engage with the FDA and believes Tavneos has a favorable benefit-risk profile[8].

Ask anything about Avacopan
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Granulomatosis with Polyangiitis trials

Common questions about Avacopan

▸What is Avacopan (Tavneos)?

A capsule taken twice a day with food, added to standard treatment that includes steroids (glucocorticoids), for adults with severe active ANCA-associated vasculitis, which covers granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)[1]. The FDA approved it on October 7, 2021[2]. On April 27, 2026, the FDA's drug center (CDER) proposed withdrawing that approval, saying unblinded study staff manipulated the results of the main study and citing serious liver injury cases with fatal outcomes[3]. Amgen, which owns the application holder ChemoCentryx, disagrees and has asked for a hearing. Tavneos stays on the US market until the FDA Commissioner decides or the company removes it, and no final decision had been published as of November 14, 2026[3][8].

▸How does Avacopan work?

Granulomatosis with polyangiitis (GPA) inflames small and medium blood vessels, mostly in the nose, sinuses, lungs, airways and kidneys, and about 90% of people with GPA carry an abnormal immune protein called ANCA (anti-neutrophil cytoplasmic antibody), which triggers inflammation when it attaches to its target[15]. Microscopic polyangiitis (MPA) is a related ANCA-associated vasculitis, and the Tavneos label covers both[1].

Complement is a set of immune proteins in the blood. When it is switched on, it releases a small fragment called C5a, which acts as a signal that activates neutrophils, a type of white blood cell, and draws them toward tissue. Avacopan blocks the receptor that C5a binds to (C5aR), so C5a cannot activate and recruit neutrophils that way. The label says the exact way this produces a benefit in ANCA-associated vasculitis has not been definitively established[1].

Tavneos is an add-on. The label says it is used together with standard treatment, including glucocorticoids, and that it does not remove the need for glucocorticoids[1].

▸What are the side effects of Avacopan?

Tavneos has no boxed warning[1]. Its label, revised in May 2026, warns first about liver damage: serious liver injury has occurred, people on Tavneos had more liver enzyme rises and liver and bile events than people on a prednisone taper in the main trial, and vanishing bile duct syndrome (a condition in which the small bile ducts in the liver are gradually destroyed) has been reported after approval, including fatal cases, mostly in Japan in people 65 and older[1]. In a March 31, 2026 safety communication, the FDA said its review of reports through October 9, 2024 found 76 cases of drug-induced liver injury with reasonable evidence of a link to avacopan, 8 of them fatal, and 7 biopsy-confirmed cases of vanishing bile duct syndrome, 3 of them fatal[5]. Amgen reports that its Japanese partner Kissei found 20 fatal serious liver injury cases among more than 8,500 patients in Japan, a count Amgen says includes cases where a link to Tavneos could not be determined[6]. The label also warns about angioedema (swelling under the skin, seen in 2 people in the trials, 1 of them hospitalized), hepatitis B coming back in people who have had it, and serious infections, including fatal ones, most often pneumonia and urinary tract infections[1]. In the main trial, side effects seen in at least 5% of people and more often than on the prednisone taper included nausea (23.5% against 20.7%), headache (20.5% against 14.0%), high blood pressure (18.1% against 17.7%), diarrhea (15.1% against 14.6%), vomiting (15.1% against 12.8%), rash (11.4% against 7.9%), fatigue (10.2% against 9.1%), upper belly pain (6.6% against 6.1%), dizziness (6.6% against 6.1%), a rise in blood creatinine (6.0% against 4.9%) and tingling or numbness (5.4% against 4.3%)[1].

▸How is Avacopan taken?

The dose is 30mg, taken as three 10mg capsules, twice a day with food. Capsules are swallowed whole and not crushed, chewed or opened. A missed dose is skipped and the next dose taken at the usual time, without doubling up[1]. Tavneos is taken together with standard treatment that includes glucocorticoids[1]. Avacopan is broken down by the liver enzyme CYP3A4, so the label lowers the dose to 30mg once a day alongside strong CYP3A4 blockers such as itraconazole and says to avoid medicines that speed that enzyme up, such as rifampin. Avacopan itself slows CYP3A4, so the label limits simvastatin to 10mg a day (20mg for people who already tolerated 80mg a day for at least a year) and says doses of other CYP3A4-processed medicines may need lowering[1]. The label gives no dose change for mild or moderate liver impairment (Child-Pugh A or B), has no data in severe impairment (Child-Pugh C) and does not recommend Tavneos with cirrhosis[1].

▸Is Avacopan FDA approved?

Yes, Avacopan (Tavneos) is FDA approved (2021) for the treatment of Granulomatosis with Polyangiitis.

▸Is Tavneos being taken off the market?

Not yet. The FDA's drug center proposed withdrawing Tavneos on April 27, 2026, and the drug stays on the US market until the FDA Commissioner decides or Amgen removes it[3].

Why the FDA proposed it: CDER says unblinded study staff manipulated the main trial's results, the original analysis was not disclosed, and it cites liver injury cases with fatal outcomes.

What Amgen did: Amgen asked for a hearing by June 1, 2026 and sent data and analyses on July 23, 2026; it says it strongly disagrees with the proposal.

Latest status: No final FDA decision had been published as of November 14, 2026.

Outside the US: The EU revoked its approval on August 4, 2026, and the UK stopped new patients from starting it on September 1, 2026.

Worth asking: The doctor who prescribes it can explain what the proposal means for each person.

Source: FDA, CDER proposes to withdraw approval of TAVNEOS; Amgen Tavneos update; EMA Tavneos page; MHRA, September 1, 2026

▸What liver tests are needed on Tavneos?

The label calls for a liver test panel before starting, every 4 weeks for the first 6 months, then as needed[1].

What is tested: ALT, AST, alkaline phosphatase and total bilirubin.

Japanese descent: The label suggests tests every 2 weeks for the first 3 months, then every 4 weeks for the next 3 months.

When it is paused or stopped: Set rises in liver enzymes or bilirubin, or symptoms such as jaundice or itching, mean stopping until liver injury from Tavneos is ruled out.

Vanishing bile duct syndrome: If it is suspected, Tavneos is stopped for good.

Source: Tavneos prescribing information, revised May 2026, DailyMed

▸How do you take Tavneos?

The dose is 30mg, three 10mg capsules, twice a day with food[1].

Swallowing: Capsules are swallowed whole, not crushed, chewed or opened.

Missed dose: The label says a missed dose is skipped and the next dose taken at the usual time, without doubling up.

Other medicines: Strong CYP3A4 blockers such as itraconazole lower the dose to 30mg once a day, and the label limits simvastatin to 10mg a day for most people.

Alongside: Tavneos is taken with standard treatment that includes steroids.

Source: Tavneos prescribing information, revised May 2026, DailyMed

▸Is Tavneos approved for microscopic polyangiitis?

Yes. The label covers adults with severe active ANCA-associated vasculitis, which it defines as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)[1].

How it is used: As an add-on to standard treatment that includes glucocorticoids, not on its own.

Children: Safety and effectiveness in children have not been established.

Status: The FDA's drug center proposed withdrawing the approval on April 27, 2026, and no final decision had been published as of November 14, 2026.

Source: Tavneos prescribing information, revised May 2026, DailyMed; FDA, CDER proposes to withdraw approval of TAVNEOS

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ChemoCentryx, Inc. via DailyMed · 2026-06-12. TAVNEOS (avacopan) capsules, prescribing information, revised May 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c93cbc0b-29a3-46a5-9c85-41815ea5cf4a
  2. U.S. Food and Drug Administration. Drugs@FDA: TAVNEOS, NDA 214487, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214487
  3. U.S. Food and Drug Administration · 2026-04-27. CDER proposes to withdraw approval of TAVNEOS. https://www.fda.gov/drugs/drug-alerts-and-statements/cder-proposes-withdraw-approval-tavneos
  4. Federal Register (FDA), Vol. 91, No. 83 · 2026-04-30. ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing. https://www.govinfo.gov/content/pkg/FR-2026-04-30/html/2026-08455.htm
  5. U.S. Food and Drug Administration · 2026-03-31. FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan) for Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis. https://www.fda.gov/drugs/drug-safety-communications/fda-identifies-cases-serious-liver-injury-patients-taking-tavneos-avacopan-severe-active-anti
  6. Amgen · 2026-07-24. Frequently Asked Questions Regarding Important TAVNEOS (avacopan) Update. https://www.amgen.com/tavneos-update
  7. Amgen · 2026-07-24. Amgen Statement on FDA Data Submission for TAVNEOS (avacopan). https://www.amgen.com/tavneos-prescribers
  8. Amgen · 2026-11-03. AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS. https://www.amgen.com/newsroom/press-releases/2026/11/amgen-reports-third-quarter-2026-financial-results
  9. New England Journal of Medicine (PMID 42377355) · 2026-06-29. Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.. https://pubmed.ncbi.nlm.nih.gov/42377355/
  10. European Medicines Agency · 2026-08-04. Tavneos: EPAR, authorisation revoked. https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos
  11. CSL · 2026-06-26. CHMP recommends revoking marketing authorisation for TAVNEOS (avacopan) in the European Union. https://newsroom.csl.com/2026-06-26-CHMP-recommends-revoking-marketing-authorisation-for-TAVNEOS-R-avacopan-in-the-European-Union
  12. Medicines and Healthcare products Regulatory Agency (GOV.UK) · 2026-09-01. MHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balance. https://www.gov.uk/government/news/mhra-concludes-review-of-avacopan-vifor-following-reassessment-of-benefit-risk-balance
  13. ClinicalTrials.gov. A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis. https://clinicaltrials.gov/study/NCT02994927
  14. ClinicalTrials.gov. Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.. https://clinicaltrials.gov/study/NCT06321601
  15. MedlinePlus Genetics, U.S. National Library of Medicine. Granulomatosis with polyangiitis. https://medlineplus.gov/genetics/condition/granulomatosis-with-polyangiitis/
  16. Genentech via DailyMed · 2025-01-06. RITUXAN (rituximab) injection, prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563
  17. Amgen. Paying for TAVNEOS. https://www.tavneos.com/support/paying-for-tavneos

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Tavneos by email

We'll email you when Tavneos's FDA label changes, when the FDA acts on it, and when new trials for Granulomatosis with Polyangiitis open. Unsubscribe anytime.

You'll get, for Granulomatosis with Polyangiitis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site